Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

This study is examining what factors predict quality of life in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are starting a new treatment, to help improve patient-centered care. **You may be eligible if:** - You have been diagnosed with CLL or SLL confirmed by pathology - You are within 7 days of starting treatment with either a BTK inhibitor (such as ibrutinib or acalabrutinib) with or without an anti-CD20 antibody, or venetoclax plus obinutuzumab - You are able to read and speak English or Spanish at an 8th grade level **You may NOT be eligible if:** - You have dementia or a traumatic brain injury - Your leukemia has spread to your central nervous system (brain or spinal cord) Talk to your doctor to see if this trial is right for you.